Track Dare Bioscience, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Dare Bioscience, Inc. DARE Open Dare Bioscience, Inc. in new tab

1.74 USD
EPS
-1.20
P/B
7.56
ROE
-2543.13
Beta
0.98
Target Price
9.67 USD
Dare Bioscience, Inc. logo

Dare Bioscience, Inc.

🧾 Earnings Recap – Q3 2025

Daré Bioscience demonstrated strong momentum in Q3 2025, advancing its dual path strategy in women's health while gearing up for the launch of its sildenafil cream, DARE to PLAY, through 503B compounding.

  • Anticipated launch of DARE to PLAY Sildenafil Cream by December 2025 marks a significant milestone in women's sexual health, utilizing a 503B outsourcing facility.
  • Ongoing advancement of clinical programs supported by grant funding, targeting key areas such as contraception and HPV, broadens the company’s innovation pipeline.
  • Strategy focuses on bridging gaps in women's health by leveraging partnerships and non-dilutive capital, enhancing market reach and operational efficiency.
  • CEO Sabrina Johnson emphasized the importance of addressing real-world needs and accelerating the transition from discovery to product availability for women's health solutions.
📅
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateMay 12, 2026
EPS-1.20
Book Value0.21
Price to Book7.56
Debt/Equity102.61
% Insiders8.572%
Growth
Revenue Growth-0.95%
Estimates
Forward P/E1.70
Forward EPS0.91
Target Mean Price9.67

DCF Valuation

Tweak assumptions to recompute fair value for Dare Bioscience, Inc. (DARE)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Dare Bioscience, Inc. Logo Dare Bioscience, Inc. Analysis (DARE)

United States Health Care Official Website Stock

Is Dare Bioscience, Inc. a good investment? Dare Bioscience, Inc. (DARE) is currently trading at 1.74 USD. Market analysts have a consensus price target of 9.67 USD. This suggests a potential upside from current levels.

Earnings Schedule: Dare Bioscience, Inc. is expected to release its next earnings report on May 12, 2026. The market consensus estimate for Forward EPS is 0.91.

Investor FAQ

Does Dare Bioscience, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Dare Bioscience, Inc.?

Dare Bioscience, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be May 12, 2026. The company currently has a trailing EPS of -1.20.

Company Profile

Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual arousal disorder; DARE-HRT1 to treat vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of dyspareunia or pain during sexual intercourse; and DARE-HPV, a fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert to treat genital human papillomavirus (HPV) infection, cervical intraepithelial neoplasia, and other HPV-related pathologies. In addition, the company develops DARE-PDM1, a hydrogel formulation of diclofenac for vaginal administration to treat primary dysmenorrhea; DARE-204 and DARE-214, injectable formulations of etonogestrel that provides contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. Further, it develops DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design controlled contraceptive option; DARE-RH1, an approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein; DARE-LBT, a vaginal thermosetting gel formulation for the delivery of live biotherapeutics; and DARE-GML, which delivers antimicrobial glycerol monolaurate intravaginally. Daré Bioscience, Inc. was founded in 2015 and is headquartered in San Diego, California.

Exchange Ticker
NMS (United States) DARE

Dividends

Historical Split Corporate Actions

Split Date Split Ratio to 1
July 20, 2017 0.100000
July 1, 2024 0.080000
Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion